Effect of TNF-α inhibition on urinary albumin excretion in experimental diabetic rats

Acta Diabetologica

Volumn 44, Issue 4, 2007, Pages 215-218

  Moriwaki, Yuji ^a   Inokuchi, Taku ^a   Yamamoto, Asako ^a   Ka, Tsuneyoshi ^a   Tsutsumi, Zenta ^a   Takahashi, Sumio ^a   Yamamoto, Tetsuya ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Diabetic nephropathy; FR167653; Infliximab; TNF ; Urinary albumin

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; ALBUMIN; CREATININE; GLUCOSE; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOPATHOGENESIS; INHIBITION KINETICS; MALE; MICROALBUMINURIA; NONHUMAN; POLYURIA; PRIORITY JOURNAL; RAT; RECOMMENDED DRUG DOSE; STREPTOZOCIN DIABETES; URINARY EXCRETION; WEIGHT REDUCTION;

ALBUMINURIA; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; DIABETES MELLITUS, EXPERIMENTAL; MALE; PYRAZOLES; PYRIDINES; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 36248953302     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-007-0007-6     Document Type: Article

References (19)

1. Hasegawa G, Nakano K, Sawada M et al (1991) Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40:1007-1012
2. Shikano M, Sobajima H, Yoshikawa H et al (2000) Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 85:81-85
3. Moriwaki Y, Yamamoto T, Shibutani Y et al (2003) Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52:605-608
4. Kalantarinia K, Awad AS, Siragy HM (2003) Urinary and renal interstitial concentrations of TNF-α increase prior to the rise in albuminuria in diabetic rats. Kidney Int 64:1208-1213
5. Navarro J, Mora C, Rivero A et al (1999) Urinary protein excretion and serum tumor necrosis factor alpha in diabetic patients with advanced renal failure: effects of pentoxifyline administration. Am J Kidney Dis 33:458-463
6. Navarro JF, Milena FJ, Mora C et al (2005) Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition. Kidney Int Suppl 99:S98-S102
7. Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563
8. Baert FJ, D'Haens GR, Peeters M et al (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116:22-28
9. Yamamoto N, Sakai F, Yamazaki H, Nakahara K, Okuhara M (1996) Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation. Eur J Pharmacol 314:137-142
10. Yamamoto N, Sakai F, Yamazaki H, Sato N, Nakahara K, Okuhara M (1997) FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-alpha, ameliorates endotoxin-induced shock. Eur J Pharmacol 327:169-174
11. Ando T, Kurita S, Takamura T (2004) The specific p38 mitogen-activated protein kinase pathway inhibitor FR167653 keeps insulitis benign in nonobese diabetic mice. Life Sci 74:1817-1827
12. Olmarker K, Nutu M, Storkson R (2003) Changes in spontaneous behavior in rats exposed to experimental disc herniation are blocked by selective TNF-alpha inhibition. Spine 28:1635-1642
13. Koshikawa M, Mukoyama M, Mori K et al (2005) Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 16:2690-2701
14. Zabel P, Schade FU, Schlaak M (1993) Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 187:447-463
15. Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR et al (1995) Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol 43:116-121
16. Sugimoto H, Shikata K, Wada J et al (1999) Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 42:878-886
17. Nakamura T, Fukui M, Ebihara I et al (1993) mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42:450-456
18. Dipetrillo K, Gesek FA (2004) Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol 24:352-359
19. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C et al (2006) Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 24:83-86